Rundu Pharma issued an announcement, expecting net profit attributable to the parent for the first half of 2026 to be between 35 million yuan and 42 million yuan, a year-on-year increase of 196.70% to 216.04%. Net profit after deducting non-recurring items is expected to be between 28 million yuan and 34 million yuan, a year-on-year increase of 162.43% to 175.81%. Basic earnings per share are expected to be between 0.10 yuan and 0.12 yuan, compared with negative 0.11 yuan in the same period last year. The performance growth is mainly due to the company actively expanding domestic and international markets, increased sales volume of active pharmaceutical ingredients and formulation products, as well as improved capacity utilization and expanded production scale at its subsidiary Jingmen Company, which drove down costs and led to significant growth in sales revenue and gross profit.
Zhuhai Rundu Pharmaceutical Co Ltd Class AExpects net profit to rise 196-216% YoY due to higher sales and lower costs.